IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Christopher F. Claiborne, et al.

Serial No.:

Unassigned

Case No.: 20282DA

Filed:

Even date herewith

For:

SUBSTITUTED IMIDAZOLES HAVING CYTOKINE

INHIBITORY ACTIVITY

The Honorable Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with 37 CFR § 1.56, and in accordance with 37 CFR § 1.97, Applicants respectfully directs the Examiner's attention to the references listed on the enclosed form PTO-1449. In accordance with 37 CFR § 1.98(3)(d), copies of the references are not enclosed because the references have been submitted to the Patent Office in U.S. Patent Application No. 09/358,199 from which this application relies for an earlier filing date. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of the references.

Applicants' attorney can be reached at the telephone number below. Correspondence should be sent to the address below. Any deficiencies in fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

DATE OF DEPOSIT DECEMPER 20, 2000
EXPRESS MAIL NO. ELEZZOTOTOLISUS
I HEREBY CERTIFY THAT THIS COMPERPONDENCE IS
BEING D eposited with the United States Postal

SERVICE AS EXPRESS MAIL "POST OFFICE TO Addressee" before 5 p.m. on the above date in an envelope addressed to assistant commissione

MAILED BY 12-0 OT DATE

Date: December 20, 2000

Respectfully submitted,

Shu M. Lee

Reg. No. 41,147

Attorney for Applicants

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-2675



Art Unit:

P.L. Morris

1625 Examiner: